Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump — Live Feedhttps://www.live-feeds.com/feed/eli-lilly-lifts-revenue-outlook-as-weight-loss-shot-demand-soars-shares-jumpContinuously updated, source-cited coverage. Eli Lilly Lifts Sales Forecast on Soaring Weight-Loss Drug Demandhttps://www.live-feeds.com/feed/eli-lilly-lifts-revenue-outlook-as-weight-loss-shot-demand-soars-shares-jumphttps://www.live-feeds.com/feed/eli-lilly-lifts-revenue-outlook-as-weight-loss-shot-demand-soars-shares-jump#u167752Sun, 01 Nov 2026 11:31:29 +0000Eli Lilly raised its annual revenue forecast by $5 billion and beat third-quarter profit estimates due to surging demand for its obesity treatment Zepbound and diabetes drug Mounjaro. The company reported robust third-quarter sales driven by GLP-1 treatments, though it trimmed its profit view due to deal charges. Shares jumped following the earnings report as financial executives look toward the next growth engine and evaluate the Medicare Bridge boon.Why it mattersPharmaceutical manufacturers face intense global demand for incretin-based therapies designed to treat diabetes and obesity. Stron